PulteGroup Inc. (PHM) and United Rentals Inc. (URI) Register Voluminous Insider Sales, Plus Three Companies with Insider Buying

Newly-Appointed CEO of This Biotechnology Company Purchases New Stake

The freshly-appointed CEO of ContraFect Corp (NASDAQ:CFRX) initiated a new stake earlier this week, a purchase most probably dictated by the company’s stock ownership guideline. Precisely, Chairman and CEO Steven C. Gilman, snatched up a 20,000-share stake on Wednesday at $2.48 apiece.

The biotechnology company that develops protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases recently offered 14 million shares of common stock and accompanying warrants to purchase up to 14 million shares at a combined public offering price of $2.50 per share and related warrant. ContraFect Corp (NASDAQ:CFRX) plans to use the roughly $32.2 million in net proceeds from this offering to fund the clinical development of its lead product candidate called CF-301, the advancement of the company’s portfolio that includes CF-404, as well as the discovery of additional product candidates. CF-301 is a lysin for the treatment of Staph aureus bacteremia, while CF-404 is being developed for the treatment of life-threatening seasonal and pandemic varieties of influenza. ContraFect has lost approximately half of its market value since the beginning of 2016. Adage Capital Management, founded by Phillip Gross and Robert Atchinson, had 1.50 million shares of ContraFect Corp (NASDAQ:CFRX) in its portfolio at the end of March.

Parent Company of an Independent Commercial Bank Also Witnesses Some Mild Insider Buying

Access National Corporation (NASDAQ:ANCX) saw one member of its executive team buy some shares earlier this week. Mark D. Moore, the President of the company’s primary subsidiary Access National Bank, purchased 3,287 shares on Monday at a price of $21.67 per share, lifting his stake to 3,687 shares.

The parent company of independent commercial bank Access National Bank, which also has three active wholly-owned subsidiaries under its umbrella, has seen its stock gain 9% since the beginning of the year. Access National Corporation (NASDAQ:ANCX) recently reported second-quarter net income of $4.88 million, which increased from $3.98 million posted a year ago. This marked the company’s 64^th consecutive quarterly profit. Moreover, the company’s boardroom approved a quarterly cash dividend of $0.15 per share, consistent with its objective to maintain a 40%-to-50% payout ratio. The dividend equates to an annual dividend yield of 2.68%. Jim Simons’ Renaissance Technologies LLC had 169,700 shares of Access National Corporation (NASDAQ:ANCX) amongst its pool of holdings on March 31.